CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤的 2023 年之路：从临床试验到真实世界
英文原题：Multiple Myeloma in 2023 Ways: From Trials to Real Life.
查看英文原题
Multiple Myeloma in 2023 Ways: From Trials to Real Life.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤是一种慢性血液系统恶性肿瘤，易反复复发。基础研究在更深入阐明疾病分子机制方面取得巨大进展，并推动新型革命性药物研发；这些药物已在临床试验中广泛评估，目前已获批并纳入治疗手段。因此，结合临床试验和真实世界数据以改善治疗策略至关重要。本综述以此为出发点，介绍目前多发性骨髓瘤的治疗方案，并比较临床试验和真实世界治疗经验。我们还将重点讨论有前景的疗法，例如T细胞接合剂和CAR-T 细胞，它们正显示出改变晚期疾病进程的疗效。
展开英文摘要原文
Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials.
These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences.
We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.
论文信息
- 作者
- Fazio M、Del Fabro V、Parrinello NL、Allegra A、Markovic U、Botta C、Accardi F、Vincelli ID
- 第一作者单位
- Post-Graduation School of Haematology, University of Catania, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy.Italy
- 通讯作者单位
- Division of Haematology and BMT, A.O.U. 'Policlinico-San Marco', 95123 Catania, Italy.Italy
- 文献类型
- 综述
- 期刊
- Current oncology (Toronto, Ont.)2023 Nov 3
- 原文标识
- PubMed 37999125 · DOI 10.3390/curroncol30110705
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →